Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 6Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 25Lung Neoplasms 8Mesothelioma, Malignant 4Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Advanced Non-squamous Non-small-cell Lung Cancer 2Uterine Cervical Neoplasms 1Solitary Fibrous Tumor, Pleural 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Head and Neck Neoplasms 1Glioma 1Esophagogastric Cancer 1Colorectal Neoplasms 1Advanced Solid Tumors 1

Interventions

Radiotherapy 9Cisplatin 9Paclitaxel 6Carboplatin 6Radiation 3Biopsy 3Bevacizumab 3balstilimab 2Topotecan 2Taxes 2Nivolumab 2Ipilimumab 2Gemcitabine 2Colposcopy 2Brachytherapy 2tislelizumab 1spartalizumab 1sitravatinib 1rucaparib 1pazopanib 1infigratinib 1fludarabine 1bemarituzumab 1atezolizumab 1aldesleukin 1Watchful Waiting 1Vinorelbine 1Vaginal Smears 1Ultrasonography 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Uterine Cervical Neoplasms × Pemetrexed × Clear all
NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Agenus Inc.

Phase 3 Withdrawn
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡